Research: Division of Pulmonary, Critical Care, and Sleep Medicine

Clinical Research

  • Outcome of Invasive Pulmonary Diagnostic Procedures: Outcome analysis of invasive diagnostic techniques such as bronchoscopy, thoracoscopy, transthoracic lung biopsy etc. in immunocompromised patients is being performed by Dr. O’Donnell and colleagues.
  • Treatment of malignant pleural effusion: Outcome analysis and cost benefit analysis of treatment of malignant pleural effusion is under study by Dr. Read.
  • Drug studies: Serious community acquired pneumonia, anti-TNF antibody in sepsis syndrome, thrombolytic therapy of pulmonary embolism.
  • DVT prophylaxis in ICU-prospected double-blind study comparing LMWH vs SQ hyparin in DVT prophylaxis funded by ACCP and overseen by Dr. Kuru.
  • Ventilator weaning protocol success by Dr. Anderson.

Enrolling Clinical Trials

  • Promis ll: A phase 3 trial to obtain information on the efficacy and safety of a drug called colistimethate sodium in comparison with a placebo, administered twice daily via an I-neb Adaptive Aerosol Delivery (AAD) system, for 12 months in adult patients affected by non-CF bronchiectasis chronically infected by a bacterium named Pseudomonas aeruginosa.
    • PI: Dr. Anne O’Donnell
  • MAC 2v3:  The purpose of the study is to learn more about whether a 2-drug therapy for Pulmonary NTM is as effective as a 3-drug therapy.
    • PI: Dr. Anne O’Donnell
  • Clofaz 001: Clofazimine in the treatment of MAC: This is a Phase 2 randomized, placebo-controlled trial to assess the clinical efficacy and safety of clofazimine in adults with pulmonary MAC disease.
    • PI: Dr. Anne O’Donnell
  • Bronchiectasis Research Registry: A database of non-cystic fibrosis (non-CF) bronchiectasis patients from major clinical and research institutions.  The goal of the Registry is to support collaborative research and assist in the planning of multi-center clinical trials for the treatment of non-CF bronchiectasis and/or non-tuberculosis mycobacteria (NTM), a progressive, chronic disease of the lungs which afflicts thousands of patients.
    • PI: Dr. Anne O’Donnell
  • Managed Access Program for Clofazimine: The population included in this program will be represented by adults (≥ 18 years old) with previous diagnosis of NTM infection with local or disseminated infection, as established by the treating physician, who have failed prior treatment or are refractory to treatment and/or are ineligible to participate in ongoing NTM clinical trials.
    • PI: Dr. Anne O’Donnell
  • UT 201/202: A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects with Pulmonary Hypertension due to Parenchymal Lung Disease. (WHO Group 3)
    • PI: Dr. Tunay Kuru
  • OPUS: US-based, observational, drug registry of Opsumit® (macitentan) new users in clinical practice.
    • PI: Dr. Tunay Kuru
  • Scleroderma Lung Study III – Combining Pirfenidone With Mycophenolate (SLSIII): A Phase II multi-center, double-blind, parallel group, randomized and placebo-controlled clinical trial addressing the treatment of patients with active and symptomatic Scleroderma-related interstitial lung disease (SSc-ILD).
    • PI: Dr. Christina Reichner

Upcoming Clinical Trials

  • ISABELA 1: A Phase 3, randomized, double-blind, parallel-group, placebo controlled multicenter study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis.                            
    • PI: Dr. Cristina Reichner
  • PHASE-Selexipag: A multicenter, randomized, double-blind, group-sequential, placebo-controlled 52-week period followed by a 104-week, single-arm, open-label period study in participants with sarcoidosis-associated pulmonary hypertension (SAPH) to assess the efficacy and safety of oral selexipag.
    • PI: Dr. Christine Fleury

Faculty Research

  • Medical Intensive Care Unit Database:The database is a census of all patients who have entered the MICU from January 1st, 2014 and today. It contains data on patient demographics, the main cause of admission, length of stay, relevant past medical history, and ICU Course.
    • PIs: Dr. Nathan Cobb, Dr. Daniel Jamieson, Dr. Rajiv Sonti